Outpatient Bispecific Program Demonstrates Safety and Tolerability in the Community Setting
The inpatient component required for step-up dosing with bispecific antibody therapy can cause financial strain for patients and reduce quality of life by removing patients form their homes and communities. This dilemma led a community oncology practice in Michigan to develop a protocol to allow for the safe administration of bispecific antibody therapy in the outpatient setting.
Marlee Bogema, MSN, APRN, FNP-C, The Cancer and Hematology Centers, Grand Rapids, Michigan, discusses findings from this program which demonstrated that outpatient administration of bispecific antibodies in the community setting is both safe and well-tolerated while also reducing the number of required inpatient days.
Bogema presented these findings at the 2024 JADPRO Live Meeting in Grapevine, Texas.
Source:
Bogema M, Malgarejo K, Molnar C, Iacopelli M, Brinker BT. Closer to Home: Building a Fully Outpatient Bispecific Program in a Community Setting. Presented at the 2024 JADPRO Live Meeting. November 14-17, 2024; Grapevine, Texas. JL1211C.
The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!
